Latigo Biotherapeutics, Inc. Common Stock (LTGO)

Latigo Biotherapeutics, Inc. Common Stock (LTGO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.1B; returns 1 day -9.4%, 1 week +7.3%.

Latigo Biotherapeutics (LTGO) is a clinical-stage biopharmaceutical company focused on the development of non-opioid pain treatments. The company's lead asset is LTG-001, a highly selective oral NaV1.8 sodium channel inhibitor.

Groups LTGO belongs to

• Recent IPOs
• Pain Management
• Biotechnology
• Biopharmaceutical
• Clinical Stage
• Healthcare
• Clinical Stage Biotech
• Neuroscience
• CNS Disorders
• Pharmaceuticals

LTGO financial model: income statement, cash flow and balance sheet